Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-018-01391-w
Abstract: BackgroundDose modification of chemotherapy for metastatic colorectal cancer (MCRC) is often needed, especially in second-line and later-line treatments due to adverse events of previous treatment and poor patient condition. No study has focused on ramucirumab… read more here.
Keywords: metastatic colorectal; folfiri; plus modified; line ... See more keywords